LIMN

Liminatus Pharma, Inc. is a pre-clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies. The Company is engaged in the development of a second generation CD47 blockade antibody designed to prevent the induction of severe anemia and thrombocytopenia observed with first generation CD47 blockades. The Company’s candidate, IBA101, is a humanized anti-CD47 monoclonal antibody. The CD47 checkpoint inhibitor’s initial indication is expected to be patients with advanced solid cancers, including non-small cell lung cancer. IBA101 is a humanized anti-human CD47 monoclonal antibody with a human IgG4 Fc, designed to preferentially bind nucleated cells, such as immune and tumor cells, while sparing anucleate cells like red blood cells and platelets. IBA101 promotes macrophage-mediated phagocytosis of tumor cells.

Wall Street analysts forecast LIMN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for LIMN is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Liminatus Pharma Inc revenue for the last quarter amounts to -701.17K USD, increased 29.06 % YoY.

Liminatus Pharma Inc. EPS for the last quarter amounts to -613720.00 USD, decreased % YoY.

Liminatus Pharma Inc (LIMN) has 0 emplpoyees as of December 16 2025.

Today LIMN has the market capitalization of 20.65M USD.